In June time, the China National Health Commission (NHC) officially announced the draft list of 1st batch of encouraged generic drugs (details of previous news are accessible here). There are 34 drugs on this list and it includes a variety of anticancer drugs like Ixabepilone, orphan drugs such as Nitisinone, and drugs that have been in short supply in China market before (e.g., Methotrexate).
However, why are these 34 drugs particularly? Below we have listed the basic information of these drugs, the market situation in China and also the registration progress in China, from which we may understand the reasons why these 34 drugs are selected into the first batch of encouraged generic drugs.
